Clinical Trials Directory

Trials / Completed

CompletedNCT00233649

DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines

Status
Completed
Phase
Study type
Observational
Enrollment
2,500 (planned)
Sponsor
AstraZeneca · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.

Conditions

Timeline

Start date
2004-05-01
First posted
2005-10-06
Last updated
2010-11-19

Locations

222 sites across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT00233649. Inclusion in this directory is not an endorsement.